Potential advantages of direct-acting thrombin inhibitors.
Evans Department of Medicine, Boston University School of Medicine, Massachusetta, USA.
G J
GJ
Philippides
J
J
Loscalzo
D000789:Angina, Unstable / Q000188:drug therapy*; D015906:Angioplasty, Balloon, Coronary; D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology*; D000990:Antithrombin III / Q000494:pharmacology; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D024764:Hirudin Therapy; D006629:Hirudins / Q000494:pharmacology*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000502:physiology; D015912:Thrombolytic Therapy
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006629:Hirudins; D000990:Antithrombin III; D006493:Heparin; D013917:Thrombin